SEOM-GEICO 上皮性卵巢癌临床指南（2023 年）。

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2024-11-01 Epub Date: 2024-07-15 DOI:10.1007/s12094-024-03531-3

Jose Alejandro Perez-Fidalgo, Fernando Gálvez-Montosa, Eva María Guerra, Ainhoa Madariaga, Aranzazu Manzano, Cristina Martin-Lorente, Maria Jesús Rubio-Pérez, Jesus Alarcón, María Pilar Barretina-Ginesta, Lydia Gaba

{"title":"SEOM-GEICO 上皮性卵巢癌临床指南（2023 年）。","authors":"Jose Alejandro Perez-Fidalgo, Fernando Gálvez-Montosa, Eva María Guerra, Ainhoa Madariaga, Aranzazu Manzano, Cristina Martin-Lorente, Maria Jesús Rubio-Pérez, Jesus Alarcón, María Pilar Barretina-Ginesta, Lydia Gaba","doi":"10.1007/s12094-024-03531-3","DOIUrl":null,"url":null,"abstract":"In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467069/pdf/","citationCount":"0","resultStr":"{\"title\":\"SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).\",\"authors\":\"Jose Alejandro Perez-Fidalgo, Fernando Gálvez-Montosa, Eva María Guerra, Ainhoa Madariaga, Aranzazu Manzano, Cristina Martin-Lorente, Maria Jesús Rubio-Pérez, Jesus Alarcón, María Pilar Barretina-Ginesta, Lydia Gaba\",\"doi\":\"10.1007/s12094-024-03531-3\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467069/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-024-03531-3\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/7/15 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-024-03531-3","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

近年来，新疗法的加入彻底改变了上皮性卵巢癌（EOC）的治疗效果。新的预测和预后生物标志物的发现，也使我们能够选择那些更有可能对靶向药物产生反应的患者。尽管如此，EOC 仍然是一种致死率很高的疾病，而且对许多新药产生耐药性的情况也很普遍。本指南旨在总结治疗 EOC 的最相关策略，帮助临床医生完成具有挑战性的诊断和治疗过程，并提供循证建议。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).

查看原文本刊更多论文

SEOM-GEICO clinical guideline on epithelial ovarian cancer (2023).

In recent years, the incorporation of new strategies to the therapeutic armamentarium has completely changed the outcomes of epithelial ovarian cancer (EOC). The identification of new predictive and prognostic biomarkers has also enabled the selection of those patients more likely to respond to targeted agents. Nevertheless, EOC is still a highly lethal disease and resistance to many of these new agents is common. The objective of this guideline is to summarize the most relevant strategies to manage EOC, to help the clinician throughout the challenging diagnostic and therapeutic processes and to provide evidence-based recommendations.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.